Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 5 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Manufacturing of Solid Dosage Forms: Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Manufacturing of Solid Dosage Forms: Overview | 10 | 4 |
| General Manufacturing Process for Solid Dosage Forms | 10 | 1 |
| Dispensing | 10 | 1 |
| Sizing | 10 | 1 |
| Powder Blending | 11 | 1 |
| Granulation | 11 | 1 |
| Drying | 11 | 1 |
| Tablet Compression | 11 | 1 |
| Packaging | 11 | 1 |
| Granulation | 12 | 1 |
| Dry Granulation | 12 | 1 |
| Introduction | 12 | 1 |
| Advantages | 12 | 1 |
| Disadvantages | 12 | 1 |
| Wet Granulation | 12 | 1 |
| Introduction | 12 | 1 |
| Limitations of Wet Granulation | 13 | 1 |
| Manufacturing of Solid Dosage Forms: Market Overview | 14 | 21 |
| Overview of Drug Formulations Market | 14 | 1 |
| Solid Dosage Form Market | 15 | 2 |
| Drivers and Restraints in the Solid Dosage Market | 17 | 1 |
| Drivers | 17 | 1 |
| Pharmaceutical Sales Continue to Grow | 17 | 1 |
| Life Cycle Management Has Grown In Importance | 17 | 1 |
| Combination Drugs | 17 | 1 |
| Rise and Acceptance of Generics to Reduce Healthcare Costs | 17 | 1 |
| Global Expansion Strategies | 18 | 1 |
| Restraints | 18 | 1 |
| Maximum Biologics are in Liquid Dosage Forms | 18 | 1 |
| Inadequate Technical Expertise | 18 | 1 |
| Unstructured Industry | 18 | 1 |
| Unstructured Regulatory Framework | 18 | 1 |
| Major Components of the Solid Dosage Forms Market | 19 | 1 |
| Active Pharmaceutical Ingredients (APIs) | 19 | 1 |
| API Drivers | 20 | 1 |
| Growth in the Generic Sector is Fuelling Growth in Demand for APIs | 20 | 1 |
| Increasing Focus on Biological Drugs Contributes to the Growth of API Demand | 20 | 1 |
| The Rising Incidence of Lifestyle and Old Age Diseases is Boosting API Demand | 20 | 1 |
| Growth in Oncology is One of the Major Contributing Factors Behind the Growth of APIs | 20 | 1 |
| Increasing Focus on High Potency APIs Helps Market Growth | 21 | 1 |
| API Market Constraints | 21 | 1 |
| Maturity of the Market in Developed Regions Restricts Global API Revenue Growth | 21 | 1 |
| High Cost of New Drug Development Becomes a Hurdle to Innovation | 21 | 1 |
| Highly Fragmented Nature of Market Leads to Intense Competition and Price Reductions | 22 | 1 |
| Regulatory Challenges Delay the Launch of Drugs | 22 | 1 |
| Excipients | 23 | 3 |
| Excipients Drivers | 26 | 1 |
| Regulatory Developments | 26 | 1 |
| Decline of the Blockbusters | 27 | 1 |
| Cost Management | 27 | 1 |
| Counterfeits | 27 | 1 |
| Using Excipients with Multiple Functionalities | 28 | 1 |
| Excipients Restraints | 28 | 1 |
| No Defined Approval Process | 28 | 1 |
| No Quality Standardization | 28 | 1 |
| Highly Fragmented Market | 28 | 1 |
| Outsourcing of Manufacturing | 29 | 1 |
| Global Pharmaceuticals CMO Market Overview | 29 | 2 |
| CMO Market Size for Solid Dosage Forms | 31 | 1 |
| Key Drivers | 32 | 1 |
| Cost Advantages in Terms of Low-cost Labor, Cheaper Raw Materials and Cheaper Export Options | 32 | 1 |
| Flexibility in Terms of Production Volume | 32 | 1 |
| Risk Mitigation against Usage of Obsolete Technology and Variable Economic Conditions | 33 | 1 |
| Increased Efficiency Due to Increased Working Capital | 33 | 1 |
| Increased Focus on Core Competencies | 33 | 1 |
| Faster Time to Market, Thereby Boosting the Profitability and Lifecycle of a Drug | 33 | 1 |
| Key Restraints | 34 | 1 |
| Evolving Cases of Accountability | 34 | 1 |
| Highly Fragmented Market | 34 | 1 |
| Adoption of Evolving Technologies Needs to Pick Up Pace | 34 | 1 |
| Manufacturing of Solid Dosage Forms: Technology Lanscape | 35 | 5 |
| Manufacturing Trends Used for Solid Dosage Forms | 35 | 1 |
| Innovative Technologies for Solid Dosage Manufacturing | 36 | 1 |
| Fluidized Hot-Melt Granulation | 36 | 1 |
| Hot-Melt Extrusion (HME) | 37 | 1 |
| Dry Emulsions | 37 | 1 |
| Bohle Tablet Coater (BTC) | 37 | 1 |
| Batch versus Continuous Process | 38 | 2 |
| Manufacturing of Solid Dosage Forms: Challenges and Unmet Needs | 40 | 2 |
| Unmet Needs | 40 | 1 |
| Solid Dosage Products Based on High Active Compounds | 40 | 1 |
| Compliance with cGMP Guidelines | 40 | 1 |
| Redesigning Manufacturing Platforms | 40 | 1 |
| Challenges | 41 | 1 |
| Regulatory Hurdles for Continuous Process Facilities | 41 | 1 |
| Innovative and Efficient Excipients Required | 41 | 1 |
| Manufacturing of Solid Dosage Forms: Regulatory Landscape | 42 | 10 |
| cGMP Guidelines | 42 | 1 |
| For API cGMP Guidelines | 43 | 4 |
| Excipient Regulation | 47 | 1 |
| Comparison of the US, Europe and Japan | 47 | 1 |
| For Excipients cGMP Guidelines | 48 | 1 |
| The IPEC Excipient Guide | 48 | 1 |
| The IQA/PQG Guide | 48 | 1 |
| Application of the PQG standard | 49 | 1 |
| IPEC and PQG Standards Comparison | 50 | 1 |
| Regulatory Basis for Supplier Qualification | 51 | 1 |
| Manufacturing of Solid Dosage Forms: Competitive Landscape | 52 | 21 |
| Patheon | 52 | 1 |
| Company Overview | 52 | 1 |
| SWOT Analysis | 52 | 2 |
| M&A, and Licensing Deals | 54 | 1 |
| AAI Pharma | 55 | 1 |
| Company Overview | 55 | 1 |
| SWOT Analysis | 55 | 2 |
| M&A, and Licensing Deals | 57 | 1 |
| Famar | 58 | 1 |
| Company Overview | 58 | 1 |
| SWOT Analysis | 58 | 1 |
| M&A, and Licensing Deals | 59 | 1 |
| EGIS Pharmaceuticals PLC | 59 | 1 |
| Company Overview | 59 | 1 |
| SWOT Analysis | 60 | 1 |
| M&A and Licensing Deals | 61 | 1 |
| STADA s Group | 62 | 1 |
| Company Overview | 62 | 1 |
| SWOT Analysis | 62 | 2 |
| M&A, and Licensing Deals | 64 | 1 |
| Mylan | 65 | 1 |
| Company Overview | 65 | 1 |
| SWOT Analysis | 65 | 2 |
| M&A, and licensing Deals | 67 | 1 |
| DSM Pharmaceutical | 68 | 1 |
| Company Overview | 68 | 1 |
| SWOT Analysis | 69 | 1 |
| M&A, and Licensing Deals | 70 | 1 |
| Teva Pharmaceutical Industries | 71 | 1 |
| Company Overview | 71 | 1 |
| SWOT Analysis | 71 | 1 |
| M&A and Licensing Deals | 72 | 1 |
| Manufacturing of Solid Dosage Forms: Emerging Companies | 73 | 5 |
| Catalent Pharma Solutions, Inc | 73 | 1 |
| Company Overview | 73 | 1 |
| Key Products and Services | 73 | 1 |
| Recent Updates Relating to Licensing Deals and Strategic Consolidations | 73 | 1 |
| Endotis Pharma, a biopharmaceutical company, entered into a co-development agreement with Catalent Pharma Solutions | 73 | 1 |
| BAVARIA Industriekapital AG, a German Industrial Holding Company, Acquired the Oral Dose Manufacturing Business (Osny) from Catalent Pharma Solutions | 73 | 1 |
| Oso Biopharmaceuticals Manufacturing, LLC, a Contract Manufacturing Company, Acquired Assets from Catalent Pharma Solutions | 73 | 1 |
| Merrion Pharmaceuticals Plc | 74 | 1 |
| Company Overview | 74 | 1 |
| Service Portfolio and Offerings | 74 | 1 |
| Recent Updates Related to Licensing Deals and Strategic Consolidations | 74 | 1 |
| Merrion Pharmaceuticals Wins US Patent for Orazol. | 74 | 1 |
| Merrion Pharmaceuticals Receives New US Patent | 74 | 1 |
| Emisphere Technologies, Inc. | 75 | 1 |
| Company Overview | 75 | 1 |
| Service Portfolio and Offerings | 75 | 1 |
| Recent Updates Related to Licensing Deals, Strategic Consolidations | 75 | 1 |
| Emisphere Technologies Completes Private Placement of $3.5m | 75 | 1 |
| Emisphere Reports Net Loss of $13.7m for Q2 2010 | 75 | 1 |
| Emisphere Reports Interim Data from Oral Eligen B12 Study | 75 | 1 |
| Chiasma Ltd. | 75 | 1 |
| Company Overview | 75 | 1 |
| Service Portfolio and Offerings | 76 | 1 |
| Recent Updates Related to Licensing Deals and Strategic Consolidations | 76 | 1 |
| Debt Financing worth $4m | 76 | 1 |
| Licensing Agreement with Novartis AG. | 76 | 1 |
| Secured $9m in Series B Preferred Stock Financing | 76 | 1 |
| Secured $44m in Series C Financing | 76 | 1 |
| Oramed Pharmaceuticals | 77 | 1 |
| Company Overview | 77 | 1 |
| Service Portfolio and Offerings | 77 | 1 |
| Recent Updates Related to Licensing Deals and Strategic Consolidations | 77 | 1 |
| Oramed Pharmaceuticals Forms Joint Venture with Laser Detect Systems | 77 | 1 |
| Oramed Completes Pivotal Phase IIb Clinical Trial of ORMD-0801 for Type 2 Diabetes. | 77 | 1 |
| Manufacturing of Solid Dosage Forms: Appendix | 78 | 4 |
| Market Definitions | 78 | 1 |
| Abbreviations | 78 | 1 |
| Research Methodology | 79 | 2 |
| Coverage | 79 | 1 |
| Secondary Research | 79 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 80 | 1 |
| Sources | 81 | 1 |